March 25, 2019 / Last updated : March 25, 2019 Benjamin Clark Pharmaceuticals

Celgene Corp Valuation – March 2019 #CELG

Celgene Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

March 24, 2019 / Last updated : March 24, 2019 Benjamin Clark Pharmaceuticals

Amgen Inc Valuation – March 2019 #AMGN

Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

March 3, 2019 / Last updated : March 3, 2019 Benjamin Clark Pharmaceuticals

AbbVie Inc Valuation – March 2019 #ABBV

AbbVie Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PB ratio.

February 25, 2019 / Last updated : February 25, 2019 Benjamin Clark Pharmaceuticals

Allergan PLC Valuation – February 2019 $AGN

Allergan plc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg ratio.

February 19, 2019 / Last updated : February 19, 2019 Benjamin Clark Pharmaceuticals

Incyte Corp Valuation – February 2019 $INCY

Incyte Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

February 19, 2019 / Last updated : February 19, 2019 Benjamin Clark Pharmaceuticals

Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

February 15, 2019 / Last updated : February 15, 2019 Benjamin Clark Pharmaceuticals

Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN

Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.

February 13, 2019 / Last updated : February 13, 2019 Benjamin Clark Pharmaceuticals

Vertex Pharmaceuticals Inc Valuation – February 2019 $VRTX

Vertex Pharmaceuticals Incorporated does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

June 26, 2018 / Last updated : June 25, 2018 Benjamin Clark Pharmaceuticals

Biogen Inc Valuation – June 2018 $BIIB

Biogen Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

June 24, 2018 / Last updated : June 24, 2018 Benjamin Clark Pharmaceuticals

Mylan NV Valuation – June 2018 $MYL

Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.

Search Results for : PRGO